Comprehensive Technology Platforms for Preclinical IBD Research

At Ace Therapeutics, we understand the complexity of inflammatory bowel disease (IBD) and the challenges it poses in drug discovery and development. That's why we've built a comprehensive technology platform designed to accelerate preclinical IBD research and help our partners generate data-rich insights.

Our brochure introduces the full scope of our cutting-edge capabilities, covering every critical dimension of IBD research

• Histopathological Analysis Platform: From H&E and immunohistochemistry to advanced quantitative pathology, we provide detailed assessments of intestinal tissue to support mechanistic studies, efficacy evaluation, and safety testing.
• In Vivo Imaging Platform: Leverage state-of-the-art imaging systems, including micro-CT, MRI, PET, endoscopy, and optical imaging, to monitor disease activity, track immune responses, and evaluate therapeutic effects in real time.
• Immunology & Molecular Analysis Platform: Explore immune dysregulation and molecular mechanisms using advanced tools for gene expression profiling, protein assays, cellular analysis, and biomarker validation.
• Gut Microbiome Analysis Platform: Harness next-generation sequencing, metagenomics, and functional validation techniques to investigate microbiome-driven mechanisms, host-microbe interactions, and therapeutic impacts.

With these platforms, we provide clients with an integrated view of intestinal inflammation, enabling deeper understanding of disease biology and supporting the development of next-generation therapies—including biologics, small molecules, and microbiome-targeted interventions.

Key Benefits for Clients

• Data-rich, multidimensional insights
• Tailored study design for specific research needs
• Integration of pathology, imaging, immunology, and microbiome perspectives
• Faster translation from preclinical studies to clinical development

You might be interested in...